Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2022 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...
September 07, 2022 02:00 ET | Source: BioNTech SE

BioNTech CEO Ugur Sahin besuchte Israel: Diskussion möglicher Zusammenarbeit bei der Pandemievorsorge und der Entwicklung innovativer Medikamente

JERUSALEM, Israel, und MAINZ, Deutschland, 7. September 2022 — BioNTech SE (Nasdaq: BNTX, „BioNTech“) gab heute bekannt, dass Prof. Ugur Sahin, CEO und Mitbegründer von BioNTech, nach Israel gereist...
September 07, 2022 02:00 ET | Source: BioNTech SE

BioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines

JERUSALEM, Israel, and MAINZ, Germany, September 7, 2022 —BioNTech SE (Nasdaq: BNTX) announced today that Prof. Ugur Sahin, CEO and Co-founder of BioNTech, visited Israel to meet with the Minister of...
September 06, 2022 07:00 ET | Source: Instil Bio

Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...
September 01, 2022 19:05 ET | Source: Sosei Group Corporation

Sosei Heptares Wins Licensing Deal of the Year and Executive of the Year at the Inaugural Informa Pharma Intelligence Awards Japan

TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in...
September 01, 2022 09:45 ET | Source: BioNTech SE

Pfizer und BioNTech erhalten positive CHMP-Empfehlung für Auffrischungsimpfung mit Omikron BA.1-angepasstem bivalenten COVID-19-Impfstoff in der Europäischen Union

CHMP-Empfehlung stützt sich auf Daten zur Sicherheit, Verträglichkeit und Immunogenität aus einer Phase-2/3-Studie mit dem Omikron BA.1-angepassten bivalenten ImpfstoffDer an Omikron BA.1 angepasste...
September 01, 2022 09:45 ET | Source: BioNTech SE

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccineThe Omicron BA.1-adapted bivalent COVID-19 vaccine...
September 01, 2022 08:00 ET | Source: AC Immune SA

AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent

Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for...
August 31, 2022 10:12 ET | Source: BioNTech SE

Pfizer und BioNTech erhalten FDA-Notfallzulassung für Auffrischungsimpfung mit an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff für Personen ab 12 Jahren

Die Notfallzulassung basiert auf klinischen und präklinischen Daten sowie Daten zur Herstellung von an Omikron angepassten bivalenten ImpfstoffenDer bivalente Omikron BA.4/BA.5 Impfstoff von Pfizer...
August 31, 2022 10:12 ET | Source: BioNTech SE

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Authorization based on clinical, pre-clinical and manufacturing data for Omicron-adapted bivalent vaccinesPfizer-BioNTech Omicron BA.4/BA.5 bivalent vaccine combines 15-µg of mRNA encoding the...